Simvastatin: A Review of its Pharmacology and Clinical Use

No abstract is available for this paper.

• Publication year

  1991

• Venue

  DICP : the annals of pharmacotherapy

• Publication date

  1991-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/106002809102500309PMID 2028634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.

  2020cited by this paper
• Clinical Experience with Simvastatin Compared with Cholestyramine

  2012cited by this paper
• Simvastatin and bezafibrate: Effects on serum lipoproteins and lecithin: Cholesterol acyltransferase activity in familial hypercholesterolaemia

  2004cited by this paper
• Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia

  2004cited by this paper
• Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia

  2004cited by this paper
• Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

  2004cited by this paper
• Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia

  2004cited by this paper
• Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).

  1990cited by this paper
• Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.

  1990cited by this paper
• Cortisol secretion in patients on simvastatin.

  1990cited by this paper
• Cortisol secretion in patients on simvastatin.

  1990cited by this paper
• The Use of Simvastatin, an HMG CoA Reductase Inhibitor, in Older Patients with Hypercholesterolemia and Atherosclerosis

  1990cited by this paper
• Effects of Simvastatin and Cholestyramine in Familial and Nonfamilial Hypercholesterolemia

  1990cited by this paper
• Comparison between low-dose simvastatin and cholestyramine in moderately severe hypercholesterolemia.

  1989cited by this paper
• Simvastatin and cholestyramine in the long‐term treatment of hypercholesterolaemia

  1989cited by this paper
• Clinical evaluation of simvastatin in patients with severe hypercholesterolemia

  1989cited by this paper
• Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.

  1989cited by this paper
• Treatment of familial hypercholesterolemia with drugs in children.

  1989cited by this paper
• Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).

  1989cited by this paper
• Simvastatin: the clinical profile.

  1989cited by this paper
• Immunological study of dystrophin in Duchenne fetus.

  1989cited by this paper
• Transient symptomatic hypotension in patients on simvastatin.

  1989cited by this paper
• Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.

  1989cited by this paper
• Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.

  1989cited by this paper
• Current therapy for hypercholesterolemia.

  1989cited by this paper
• Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.

  1989cited by this paper
• Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly

  1989cited by this paper
• HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.

  1989cited by this paper
• Simvastatin (MK 733): an effective treatment for hypercholesterolemia.

  1989cited by this paper
• Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels.

  1989cited by this paper
• Comparison between low-dose simvastatin and cholestyramine in moderately severe hypercholesterolemia.

  1989cited by this paper
• Efficacy and tolerability of simvastatin (MK-733).

  1989cited by this paper
• Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.

  1988cited by this paper
• Efficacy and long-term adverse effect pattern of lovastatin.

  1988cited by this paper
• Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.

  1988cited by this paper
• Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover.

  1988cited by this paper
• Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.

  1988cited by this paper
• Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.

  1988cited by this paper
• Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.

  1988cited by this paper
• Lovastatin and rhabdomyolysis.

  1988cited by this paper
• Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor

  1988cited by this paper
• HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

  1988cited by this paper
• Simvastatin, a competitive inhibitor of HMG‐CoA reductase, lowers cholesterol saturation index of gallbladder bile

  1988cited by this paper
• Simvastatin plus low-dose colestipol in the treatment of severe familial hypercholesterolemia

  1988cited by this paper
• Effects of MK‐733 on plasma lipid and lipoprotein levels in subjects with hypercholesterolaemia

  1987cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

  1987cited by this paper
• Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

  1987cited by this paper
• 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin.

  1986cited by this paper
• Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.

  1986cited by this paper
• Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia.

  1986cited by this paper
• Contemporary recommendations for evaluating and treating hyperlipidemia.

  1986cited by this paper
• Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.

  1986cited by this paper
• Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.

  1986cited by this paper
• Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia

  1986cited by this paper
• Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia.

  1985cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

  1984cited by this paper
• Plasma mevalonate as a measure of cholesterol synthesis in man.

  1984cited by this paper
• The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.

  1984cited by this paper
• Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.

  1984cited by this paper
• Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.

  1984cited by this paper
• Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.

  1984cited by this paper
• Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.

  1983cited by this paper
• Abortions because of unavailability of prenatal diagnosis.

  1981cited by this paper
• Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

  1981cited by this paper
• Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

  1980cited by this paper
• Andrew Moynihan Claye.

  1977cited by this paper
• Regulation of HMG-CoA reductase.

  1976cited by this paper
• Regulation of cholesterol metabolism. 3.

  1970cited by this paper
• Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods.

  1969cited by this paper

• Enhancement of the Solubility of Simvastatin by Utilizing Two Distinct Types of Excipient Compositions, L-Isoleucine and Sodium Docusate

  2025cites this paper
• Use of an Uncertainty Profile to Validate High-Performance Liquid Chromatography (HPLC) for the Simultaneous Determination of Statins in Synthetic Pharmaceutical Products

  2023cites this paper
• Enhanced osseointegration of drug eluting nanotubular dental implants: An in vitro and in vivo study

  2023cites this paper
• The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action

  2023cites this paper
• A drift on liposomes to proliposomes: recent advances and promising approaches

  2022cites this paper
• BAPST. A Combo of Common use drugs as metabolic therapy of cancer-a theoretical proposal.

  2021cites this paper
• Bioequivalence assessment of two simvastatin tablets in healthy Taiwanese volunteers

  2020cites this paper
• RETRACTED: The Enhanced Cytotoxic and Pro-Apoptotic Effects of Optimized Simvastatin-Loaded Emulsomes on MCF-7 Breast Cancer Cells

  2020cites this paper
• Effect of Simvastatin on the Skeletal Muscles of Senile Male Albino Rats and Possible Protective Role of L- Carnitine. A Histological Study

  2019cites this paper
• Simvastatin induces apoptosis in PTEN‑haploinsufficient lipoma cells.

  2018cites this paper
• Intranasal optimized solid lipid nanoparticles loaded in situ gel for enhancing trans-mucosal delivery of simvastatin

  2018cites this paper
• Simvastatin reduces adrenal catecholamine secretion evoked by stimulation of cholinergic nicotinic and angiotensinergic AT1 receptors

  2018cites this paper
• Comparative pharmacokinetic and tolerability evaluation of two simvastatin 20 mg formulations in healthy Korean male volunteers

  2017cites this paper
• Mechanisms of simvastatin-induced vasodilatation of rat superior mesenteric arteries.

  2016cites this paper
• Heterologous expression of a lichen polyketide synthase in filamentous fungi

  2015cites this paper
• Effects of red mold dioscorea with pioglitazone, a potentially functional food, in the treatment of diabetes

  2015cites this paper
• Inhibition of Cholesterol Biosynthesis

  2015cites this paper
• Simvastatin: Biological Production, Therapeutic Applications and Proposed Alternative Hypothesis for Biosynthesis

  2014cites this paper
• Red mold dioscorea decreases blood pressure when administered alone or with amlodipine and is a potentially safe functional food in SHR and WKY rats

  2013cites this paper
• Red mold dioscorea: a potentially safe traditional function food for the treatment of hyperlipidemia.

  2012cites this paper
• Pharmacokinetic Interaction between Simvastatin and Nicardipine

  2009cites this paper
• Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders

  2008cites this paper
• Prodrugs: design and clinical applications

  2008cites this paper
• In Vitro Characterization Of Simvastatin Loaded Microspheres In The PolyRing Device

  2008influential citation
• Locally applied Simvastatin improves fracture healing in mice

  2007cites this paper
• La prescrizione e l'uso dei farmaci "equivalenti"

  2007cites this paper
• Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects

  2007cites this paper
• Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.

  2006cites this paper
• Effect of simvastatin on the oxidation of native and modified lipoproteins.

  2005cites this paper
• Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil.

  2005cites this paper
• Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples.

  2003cites this paper
• Transformations of cyclic nonaketides by Aspergillus terreus mutants blocked for lovastatin biosynthesis at the lovA and lovC genes.

  2003cites this paper
• Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review)

  2003cites this paper
• Effects of Simvastatin on Endothelial Function After Chronic Inhibition of Nitric Oxide Synthase by l-NAME

  2003cites this paper
• Anti-atherosclerotic activity1

  2002cites this paper
• Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca(2+) homeostasis.

  2001cites this paper
• Study of the drug–drug interaction between simvastatin and cisapride in man

  2001cites this paper
• Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat

  2000influential citation
• Use of Simvastatin Treatment in Patients With Combined Hyperlipidemia in Clinical Practice

  2000cites this paper
• Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. For the Simvastatin Combined Hyperlipidemia Registry Group.

  2000cites this paper
• Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats.

  1999cites this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

  1998cites this paper
• Chronic actinic dermatitis due to simvastatin

  1998cites this paper
• Simvastatin‐tacrolimus and simvastatin‐cyclosporin interactions in rats

  1998cites this paper
• Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

  1997cites this paper
• Anti-atherosclerotic activity

  1997cites this paper
• Efficacy and Pharmacokinetics of Simvastatin in Heart Transplant Recipients

  1995cites this paper
• Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia

  1995cites this paper
• Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.

  1995cites this paper
• Pharmacokinetic drug interactions. Part 3: Drugs P-Z.

  1995cites this paper
• [Hydroxymethylglutaryl coenzyme A reductase inhibitors].

  1994cites this paper
• Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.

  1993cites this paper
• Clinical Pharmacokinetics and Practical Applications of Simvastatin

  1993cites this paper
• HMG-CoA Reductase Inhibitor Use in the Aged

  1992cites this paper
• Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

  1992cites this paper
• HMG-CoA reductase inhibitor use in the aged. A review of clinical experience.

  1992cites this paper
• Simvastatin

  1992cites this paper
• Pharmacological characterization of potent and selective Free Fatty Acid Receptor 1 ( FFA 1 / GPR 40 ) agonists for the treatment of type 2 diabetes View project

  year unknowncites this paper
• International Journal of Indigenous Herbs and Drugs

  year unknowncites this paper